167 related articles for article (PubMed ID: 7912520)
1. Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
Adams JD; Flora KP; Goldspiel BR; Wilson JW; Arbuck SG; Finley R
J Natl Cancer Inst Monogr; 1993; (15):141-7. PubMed ID: 7912520
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of protaxols.
Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
[TBL] [Abstract][Full Text] [Related]
3. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
Nornoo AO; Osborne DW; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process.
Park JH; Yan YD; Chi SC; Hwang DH; Shanmugam S; Lyoo WS; Woo JS; Yong CS; Choi HG
J Pharm Pharmacol; 2011 Apr; 63(4):491-9. PubMed ID: 21401600
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo.
Hassan S; Dhar S; Sandström M; Arsenau D; Budnikova M; Lokot I; Lobanov N; Karlsson MO; Larsson R; Lindhagen E
Cancer Chemother Pharmacol; 2005 Jan; 55(1):47-54. PubMed ID: 15565443
[TBL] [Abstract][Full Text] [Related]
6. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
8. Novel Taxol formulations: Taxol-containing liposomes.
Straubinger RM; Sharma A; Murray M; Mayhew E
J Natl Cancer Inst Monogr; 1993; (15):69-78. PubMed ID: 7912532
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation of paclitaxel-containing liposomes.
Holvoet C; Vander Heyden Y; Lories G; Plaizier-Vercammen J
Pharmazie; 2007 Feb; 62(2):126-32. PubMed ID: 17341033
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
Zhang JA; Anyarambhatla G; Ma L; Ugwu S; Xuan T; Sardone T; Ahmad I
Eur J Pharm Biopharm; 2005 Jan; 59(1):177-87. PubMed ID: 15567316
[TBL] [Abstract][Full Text] [Related]
11. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
[TBL] [Abstract][Full Text] [Related]
12. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.
Park JH; Chi SC; Lee WS; Lee WM; Koo YB; Yong CS; Choi HG; Woo JS
Arch Pharm Res; 2009 Jan; 32(1):139-48. PubMed ID: 19183887
[TBL] [Abstract][Full Text] [Related]
13. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability.
Bouquet W; Ceelen W; Fritzinger B; Pattyn P; Peeters M; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2007 Jun; 66(3):391-7. PubMed ID: 17240125
[TBL] [Abstract][Full Text] [Related]
15. A review of paclitaxel (Taxol) administration, stability, and compatibility issues.
Boyle DA; Goldspiel BR
Clin J Oncol Nurs; 1998 Oct; 2(4):141-5. PubMed ID: 10232160
[TBL] [Abstract][Full Text] [Related]
16. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
Gogate US; Schwartz PA; Agharkar SN
Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
[TBL] [Abstract][Full Text] [Related]
17. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
Le Garrec D; Gori S; Luo L; Lessard D; Smith DC; Yessine MA; Ranger M; Leroux JC
J Control Release; 2004 Sep; 99(1):83-101. PubMed ID: 15342183
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
[TBL] [Abstract][Full Text] [Related]
19. Total synthesis of taxol.
Nicolaou KC; Yang Z; Liu JJ; Ueno H; Nantermet PG; Guy RK; Claiborne CF; Renaud J; Couladouros EA; Paulvannan K
Nature; 1994 Feb; 367(6464):630-4. PubMed ID: 7906395
[TBL] [Abstract][Full Text] [Related]
20. Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics.
Nornoo AO; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):117-23. PubMed ID: 17869458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
